Article

Successful phase 2 trial, Aerie Pharmaceuticals, Inc.’s dry eye candidate advancing to phase 3

Author(s):

David Hutton

David Wirta, MD, Medical Director for the Eye Research Foundation, Inc., presents the data of Aerie Pharmaceuticals, Inc.’s novel dry eye product candidate, AR-15512 (0.003%). The successful phase 2 results has propelled the product into phase 3 trials.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
Related Content
Q&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trial
June 11th 2025

Q&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trial

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Q&A: Siegfried Priglinger, MD, on the long-term outcomes of gene therapy in preschool kids
June 9th 2025

Q&A: Siegfried Priglinger, MD, on the long-term outcomes of gene therapy in preschool kids

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Q&A: Jay Chhablani, MD, discusses 3D choroidal vasculature analysis
June 8th 2025

Q&A: Jay Chhablani, MD, discusses 3D choroidal vasculature analysis

(Image credit: AdobeStock/zinkevych) FDA nod for acoltremon: What its approval means for clinicians and patients
June 7th 2025

FDA nod for acoltremon: What its approval means for clinicians and patients

© 2025 MJH Life Sciences

All rights reserved.